528150
PARP Inhibitor VIII, PJ34
The PARP Inhibitor VIII, PJ34, also referenced under CAS 344458-15-7, controls the biological activity of PARP. This small molecule/inhibitor is primarily used for Cell Structure applications.
Synonym(s):
PARP Inhibitor VIII, PJ34
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
C17H17N3O2 · xHCl
CAS Number:
Molecular Weight:
295.34 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77
Recommended Products
Quality Level
Assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
desiccated (hygroscopic)
protect from light
color
white
solubility
water: 5 mg/mL
shipped in
ambient
storage temp.
−20°C
InChI
1S/C17H17N3O2.ClH/c1-20(2)10-16(21)18-11-7-8-15-14(9-11)12-5-3-4-6-13(12)17(22)19-15;/h3-9H,10H2,1-2H3,(H,18,21)(H,19,22);1H
InChI key
RURAZZMDMNRXMI-UHFFFAOYSA-N
General description
A cell-permeable, water-soluble phenanthridinone-derivative that acts as a potent inhibitor of poly(ADP-ribose) polymerase (PARP; EC50 = 20 nM). Shown to be about 10,000 times more potent than the prototypical PARP inhibitor, 3-Aminobenzamide (Cat. No. 165350; EC50 = 200 µM). Does not act as an antioxidant at higher concentrations (1 µM to 10 mM). Exhibits neuroprotection in in vivo and in vitro models of stroke. Also available as a 20 mM solution in H2O(Cat. No. 528151).
A water-soluble phenanthridinone-derivative that acts as a potent anti-inflammatory agent and an inhibitor of poly(ADP-ribose) polymerase (PARP; EC50 = 20 nM). Shown to be about 10,000-fold more potent than the prototypical PARP inhibitor, 3-Aminobenzamide (Cat. No. 165350) (EC50 = 200 µM). Suppresses neutrophil infiltration and nitric oxide production in peritonitis. Does not act as an antioxidant even at higher concentrations (1 µM to 10 µM). PJ34 inhibits peroxynitrite-induced cell necrosis with an (EC50 = 20 nM). Exhibits neuroprotective effects in in vivo and in vitro models of stroke.
Biochem/physiol Actions
Cell permeable: yes
EC50 = 20 nM inhibiting poly(ADP-ribose) polymerase (PARP)
Primary Target
PARP
PARP
Product does not compete with ATP.
Reversible: no
Packaging
Packaged under inert gas
Warning
Toxicity: Standard Handling (A)
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.
Other Notes
Abdelkarim, G.E., et al. 2001. Int. J. Mol. Med.7, 255.
Garcia-Soriano, F.G., et al. 2001. Nature Med. 7, 108.
Mabley, G.J., et al. 2001. Inflamm. Res.50, 561.
Garcia-Soriano, F.G., et al. 2001. Nature Med. 7, 108.
Mabley, G.J., et al. 2001. Inflamm. Res.50, 561.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Joelle C Boulos et al.
Acta pharmacologica Sinica, 44(11), 2265-2281 (2023-06-22)
The majority of blood malignancies is incurable and has unforeseeable remitting-relapsing paths in response to different treatments. Cynaropicrin, a natural sesquiterpene lactone from the edible parts of the artichoke plant, has gained increased attention as a chemotherapeutic agent. In this
Shiori Kuraoka et al.
Molecular & cellular proteomics : MCP, 100153-100153 (2021-10-01)
Mass spectrometry-enabled ADP-ribosylation workflows are developing rapidly, providing researchers a variety of ADP-ribosylome enrichment strategies and mass spectrometric acquisition options. Despite the growth spurt in upstream technologies, systematic ADP-ribosyl (ADPr) peptide mass spectral annotation methods are lacking. HCD-dependent ADP-ribosylome studies
Pablo Iglesias et al.
International journal of molecular sciences, 24(10) (2023-05-27)
In recent years, new therapies have been developed based on molecules that target molecular mechanisms involved in both the initiation and maintenance of the oncogenic process. Among these molecules are the poly(ADP-ribose) polymerase 1 (PARP1) inhibitors. PARP1 has emerged as
Han-Wei Liu et al.
Neuron, 111(10), 1609-1625 (2023-03-16)
Stroke prognosis is negatively associated with an elevation of serum bilirubin, but how bilirubin worsens outcomes remains mysterious. We report that post-, but not pre-, stroke bilirubin levels among inpatients scale with infarct volume. In mouse models, bilirubin increases neuronal
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service